{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"143","value":"92"},{"groupId":"OG001","lowerLimit":"-41","upperLimit":"49","value":"-9"},{"groupId":"OG002","lowerLimit":"-218","upperLimit":"-218","value":"-218"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"End of cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-53","upperLimit":"56","value":"-39"},{"groupId":"OG001","lowerLimit":"-32","upperLimit":"41","value":"-29"},{"groupId":"OG002","lowerLimit":"-190","upperLimit":"-190","value":"-190"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Treatment discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75","upperLimit":"181","value":"76"},{"groupId":"OG001","lowerLimit":"-9","upperLimit":"45","value":"31"},{"groupId":"OG002","lowerLimit":"-175","upperLimit":"-175","value":"-175"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"6-month follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"169","upperLimit":"169","value":"169"},{"groupId":"OG001","lowerLimit":"-16","upperLimit":"104","value":"31"},{"groupId":"OG002","lowerLimit":"-84","upperLimit":"-84","value":"-84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"12-month follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Phase I, Arm A (VR-DA-EPOCH) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1)","id":"OG000","title":"Phase I: VR-DA-EPOCH, Dose Level 1"},{"description":"Phase I, Arm A (VR-DA-EPOCH) with Vorinostat at 400 mg once a day on days 1-5 of a cycle (Phase I Dose Level 2)","id":"OG001","title":"Phase I: VR-DA-EPOCH, Dose Level 2"},{"description":"Phase I, Arm C (VR-CHOP) with Vorinostat at 300 mg once a day on days 1-5 of a cycle (Phase I Dose Level 1 for low risk participants). This arm was discontinued due to low accrual.","id":"OG002","title":"Phase I: VR-CHOP, Dose Level 1"}],"paramType":"MEDIAN","populationDescription":"Eligible participants who completed at least 1 cycle of treatment with evaluable data.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 months","title":"Changes in Absolute CD4 Cell Counts (Phase I)","type":"SECONDARY","unitOfMeasure":"cell/mm^3"}